Two bodies are responsible for examining biotech patent applications in Brazil, but this approach causes problems, as Marcelo Oliveira de Souza and Antonio Alexandre Moura dos Santos of Di Blasi, Parente & Associados report.
With specialist IP providers offering post-M&A services at lower cost than traditional law firms, have clients been overspending in the past? Melissa Pillote on behalf of Dennemeyer reports.
There is some debate among Russian legal professionals about whether “selection inventions” are considered patentable, but the answer seems clear, says Valery Djermakian of Gorodissky & Partners.
‘Technological intelligence’ is very important for extracting maximum value from technology transfer deals, and life sciences companies should use it to their advantage, says Montserrat González-Álvarez of Leyva, Montenegro, Trigueros Abogados.
New legislation in Brazil aims to create a balance between using genetic resources for scientific advancement and spreading the benefits among local communities fairly, as Gabriel Di Blasi of Di Blasi, Parente & Associados and Eduardo Emrich of Biominas Brasil explain.
In a world where research projects are increasingly carried out by several parties in different countries, companies should consider a number of IP-related issues before embarking on multiterritorial collaborations, say Oliver Laing and Tony Proctor of Potter Clarkson.
Over the past few years China’s life sciences sector has become a hive of activity as specialist IP courts have been implemented and M&A activity has ramped up. LSIPR assesses some of these developments.
In September 2016, the Francis Crick Institute opened the doors to its multimillion-pound new home in London. With a wide range of research being undertaken, LSIPR examines the role of IP and the associated challenges for the organisation.
Dolly the Sheep, which would have been 20 this year, raised the possibility of cloning and forced politicians and IP practitioners to address the ethics of the process, with differing results in the US and the UK, as LSIPR reports.
On December 7, LSIPR will be hosting the Life Sciences Patents Network Europe 2016 at the Bloomsbury Hotel in London. Here we preview the main talking points.